跳到正文
FDA 官方药品与生物制品信息·· 4 天前AI 评分30

FDA药品质量办公室年度《药品质量状况报告》

Report on the State of Pharmaceutical Quality

AI 导读

FDA药品质量办公室每年发布《药品质量状况报告》,分享关键质量数据、趋势评估及质量监测项目的见解,以刻画美国药品供应链质量状况。报告每年更新,提供制药商、其产品及上市后质量缺陷的当前与累计数据,并介绍监测与提升药品质量的新兴方法。FDA将该报告部分用于支持监管决策和质量监测活动。

正文 · 原文

Everyone deserves confidence in their next dose of medicine. A quality medicine is safe, effective, and available for the people who need it. The Office of Pharmaceutical Quality’s mission is to assure that quality medicines are available to the American public. Drug manufacturers are responsible for complying with regulations and ensuring their products meet quality standards. Quality is complex, involving the product, process, facility, and supply chain. There is no single tool that can assure quality, but a combination of complementary tools can make it feasible to surveil the U.S. pharmaceutical market. The Report on the State of Pharmaceutical Quality is published annually to share key quality data, assessment of trends, and insights about quality surveillance programs with the public. 

The annual Report on the State of Pharmaceutical Quality is intended to help characterize the quality of the U.S. drug supply chain. It is updated each year to provide current and cumulative data about pharmaceutical manufacturers, their products, and postmarket quality defects. The report also highlights emerging approaches to surveil, characterize, and advance pharmaceutical quality. FDA uses the Report on the State of Pharmaceutical Quality, in part, to inform regulatory decision making and quality surveillance activities.

The Report on the State of Pharmaceutical Quality from Previous Years

来源:FDA 官方药品与生物制品信息 · fda.gov